6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01836432 [Disease Site] Pancreatic Cancer [Description] 
A Phase III Study of FOLFIRINOX with or without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description